UEG Week 2022

Personalized therapy - de-escalation strategies

The benefit of early intervention in CD

Is IL-23 the super target?

What is the best dose of adalimumab in CD?

Treat-to-target still alive?

What is new in anti-TNFα therapy?

Treat-to-target with ustekinumab - why didn't it work?

Enhanced treatment algorithm for the management of CD

Once more a shocking message: be aware of steroids!

Explosion of new drugs

Oral anti-integrin therapy in IBD - new data, new chances?

Combination therapy: week 38 efficacy and safety data from the VEGA study

Treating the patient as a whole

Anti-IL-23 monoclonal antibodies: is it better to target IL-23 only than IL-23 and IL-12?

No matter what you use - treat early!

Postoperative monitoring matters!

Longterm potential benefit of a combIo therapy

Thinking out of the box - co-medication of the elderly

Pharmacokinetics of ustekinumab in the STARDUST trial

T reg - a new therapeutic target in IBD?

Treat-to-target strategy is superior to conventional step-care in active patients to gain remission

You can still treat severe biofailure in CD

Small molecules in crohn's disease

VEGA - the story continues

TYK2 Deucravacitinib in ulcerative colitis

Μπορείς ακόμη να θεραπεύσεις ανθεκτική στα βιολογικά νόσο του Crohn

Small molecules nel morbo di crohn

VEGA - l'histoire continue

TYK2 Deucravacitinib bei Colitis ulcerosa

Doustna terapia antyintegrynowa - nowe dane, nowe nadzieje?

Ακόμα ένα πολύ ανησυχητικό μήνυμα: Πρόσεχε τα κορτικοστεροιδή!

Les résultats à long terme d'une combIothérapie

Terapia di combinazione: efficacia e sicurezza a 38 settimane nello studio VEGA

Explosión de nuevos fármacos

Was tun nach der Operation?

Ανεξάρτητα του τι θα χορηγήσεις χορήγησέ το έγκαιρα!

Treating the patient as a whole

Thinking out of the box - Einfluss der Begleitmedikation bei älteren Patienten

Una strategia “Treat-to-target” è superiore rispetto and un approccio convenzionale nel raggiungimento della remissione in pazienti con malattia attiva

T reg - nowy cel terapeutyczny w IBD?

Anticorps anti-IL-23: est-il préferabble de cibler l'IL-23 seule plutôt que l'IL-12 et l'IL-23?

S1P receptor modulators

Update on IL-23 inhibition in UC

1st JAK inhibitor in CD - a game changer?

Update on JAK inhibition in UC

Upadacitinib - induction therapy in CD

Estrasimod in moderate to severe active UC

The era of small molecules

Persistance on therapy and real-world clinical effectiveness of Tofacitinib in ulcerative colitis: data from the ENEIDA registry

Selective IL-23 blockade

Upadacitinib maintenance therapy - final results from U-ACHIEVE

The 1st JAKi in CD

Histological response and remission induced by mirikizumab

JAK-inhibition

Ozanimod works in young and old UC patient

Final efficacy and safety results from Upadacitinib 52 weeks maintenance trial in UC patients

Risankizumab in refractory CD patients

VEGA & LUCENT studies

Upadacitinib - Induktionsdaten bei CD

Persistenza in terapia ed efficaci clinica di Tofacitinib in colite ulcerosa: dati dal registro ENEIDA

Selective IL-23 Blockade

The area of small molecules

JAK-Inhibition

Risultati finali di efficacia e sicurezza a 52 settimane di Upadacitinib in colite ulcerosa

Risankizumab dans la maladie de Crohn réfractaire

VEGA & LUCENT studi clinici

Treating the elderly - closer surveillance and the importance of co-medication

Updated safety data on JAK inhibitors

Steroid effects as treatment goals: quality of life and steroid free remission

Urgency - putting the focus on an important endpoint!

Patient reported outcomes in IBD

Urgency matters!

New endpoints in IBD

Filgotinib is efficacious in inducing and maintaining histological remission in UC

Neue Studienendpunkte in IBD

Patienten gerichtete Endpunkte bei CED

Whats's the origin of Crohn's genetics ? The history of IL-23 receptor genetics in Europe

Explosion of Spanish contributions

Explosión de las comunicaciones españolas

Wo kommt die Crohn-Genetik her? Die Historie der IL-23 Rezeptorgenetik in Europa

Personalised therapy in IBD

Individualisierte Therapie bei CED